Combining PARP and CDK4/6 inhibitors with endocrine therapy for advanced breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical study focuses on evaluating the efficacy of a combination of PARP inhibitor Fluzoparib, CDK4/6 inhibitor Dalpiciclib, and endocrine therapy in patients with HR+/HER2- advanced breast cancer, specifically those with the SNF3 subtype. The study aims to enroll females aged 18 to 75 with confirmed histological diagnosis and measurable disease. The results will inform future randomized controlled phase III studies with a larger sample size to further assess treatment effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Females ≥18 years and ≤ 75 years old;
* Histologically confirmed HR + / HER2- invasive breast cancer (specific definition: immunohistochemical detection of ER\> 10% tumor cell positive is defined as ER positive, PR\> 10% tumor cell positive is defined as PR positive, ER and / or PR Positive is defined as HR positive; HER2 0-1 + or HER2 is ++ but negative followed by FISH detection, no amplification, defined as HER2 negative);
* Subtype of similarity network fusion-3 (SNF-3) confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan University Affiliated Cancer Hospital • Locally advanced breast cancer (incapable of radical local treatment) or recurrent metastatic breast cancer;
* Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); or unmeasurable lytic or mixed (osteolytic + osteoblastic) bone lesions in the absence of measurable lesions;
* Has adequate bone marrow function: absolute neutrophil count \> 1.5x10ˆ9 /L; platelet count \> 75x10ˆ9 /L, hemoglobin \> 9g/dL;
* Patients had received no previous chemotherapy or targeted therapy for metastatic disease
* Has adequate liver function and kidney function: serum creatinine
* ECOG score ≤ 2 and life expectancy ≥ 3 months;
* Participants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.

Exclusion Criteria:

* Treatment with chemotherapy, radiotherapy, immunotherapy or surgery (outpatient clinic surgery excluded) for metastatic disease
* Symptomatic, untreated, or actively progressing CNS metastases(glucocorticoids or mannitol needed to control symptoms);
* Significant cardiovascular disease(including congestive heart failure, angina pectoris, myocardial infarction or ventricular arrhythmia in the last 6 months);
* is pregnant or breast feeding;
* Malignant tumors in the past five years (except cured skin basal cell carcinoma and cervical carcinoma in situ).

Where it's running

• Breast cancer institute of Fudan University Cancer Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Zhimin Shao
• Email: zhimingshao@yahoo.com
• Phone: 86-021-64175590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Decision Support Tool for People with Advanced Breast Cancer

  This study tests a decision support tool called COAST to help people with stage IV breast cancer talk with their doctors and share treatment preferences.

  Recruiting at 3 sites Weill Medical College of Cornell University · Brooklyn, New York and 2 other locations · NCT07635147

• HER2-PET to Predict T-DXd Benefit in Advanced Breast Cancer

  This study tests whether HER2-PET imaging can help predict how well T-DXd will work for adults with advanced HER2-positive or HER2-low breast cancer receiving the drug.

  Recruiting Fudan University · Shanghai · NCT07586215

• Nutrition awareness for women after non-metastatic breast cancer

  This online program tests whether an educational brochure and short surveys can help women who have finished treatment for non-metastatic breast cancer recognize unhealthy processed foods and be willing to change their diet.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07389967

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

• First-line Sacituzumab Govitecan for Advanced Untreated Triple-Negative Breast Cancer

  This study tests whether Sacituzumab Govitecan can slow disease progression when given as a first treatment to adults with advanced triple-negative breast cancer who have not yet received treatment in the advanced setting.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia · NCT07299409

• OM-RCA-01 (anti-FGFR1 antibody) for metastatic tumors that express FGFR1

  This trial will try OM-RCA-01, an IV antibody given every two weeks, in adults with metastatic cancers whose tumors test positive for FGFR1 and who have progressed after standard treatments.

  Recruiting at 4 sites Phase 1/2 Kidney Cancer Research Bureau · Kazan' and 4 other locations · NCT07292168

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.